Modified Release Formulations and Uses Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 16/892,641, filed Jun 4, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,654,113 | Modified Release Formulations and Uses Thereof In force · High confidence | Sunovion Pharmaceuticals Inc. | In force | High confidence | ||
| US 12,161,758 | Modified Release Formulations and Uses Thereof In force · High confidence | Sunovion Pharmaceuticals Inc. | In force | High confidence | ||
| US 11,160,758 | Modified Release Formulations and Uses Thereof Lapsed Nov 2, 2025 on the fee record High confidence | Sunovion Pharmaceuticals Inc. | Lapsed Nov 2, 2025 on the fee record | High confidence |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Sunovion Pharmaceuticals Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.